Sun Pharma Receives Warning Letter from USFDA Relating to Its Gujarat Plant

by Dr. Trupti Shirole on  December 23, 2015 at 12:01 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Drug major Sun Pharmacuetical Industries Ltd has received a warning letter from US Food and Drug Administration (USFDA) relating to its facility in Halol in Gujarat.

The letter was a result of the inspection done by the USFDA at Halol plant in September 2014.
 Sun Pharma Receives Warning Letter from USFDA Relating to Its Gujarat Plant
Sun Pharma Receives Warning Letter from USFDA Relating to Its Gujarat Plant

In a statement Sun Pharma said, "We would respond to the warning letter with a detailed plan within the stipulated timeframe."

Dilip Shanghvi, managing director, said, "While our team is working hard to ensure that the commitments made to the USFDA in September 2014 are fully completed, we will continue to cooperate with the USFDA and undertake any additional steps necessary to ensure that the US agency is completely satisfied with our remediation of the Halol facility."

Post the September 2014 inspection, the USFDA has withheld future product approvals from the Halol facility.

Source: IANS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive